Bertram Opalka

3.3k citations

99 papers · 2.3k indexed · h-index 26

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 54
- Chronic Myeloid Leukemia Treatments 32
- Acute Myeloid Leukemia Research 16
- Multiple Myeloma Research and Treatments 9
Molecular Biology 41
- RNA Interference and Gene Delivery 9

Co-authors: S. Seeber (36 shared papers)O. Kloke (21 shared papers)Dietrich W. Beelen (7 shared papers)N. Niederle (19 shared papers)Ahmet Elmaağaclı (7 shared papers)Tassilo Moritz (10 shared papers)Philipp Schütt (6 shared papers)J. Schütte (14 shared papers)
Journals: Blood (12 papers)British Journal of Haematology (5 papers)Leukemia Research (4 papers)Genomics (3 papers)European Journal of Immunology (3 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Bertram Opalka

97 papers receiving 2.2k citations

Peers

Countries citing papers authored by Bertram Opalka

Since Specialization

Citations

This map shows the geographic impact of Bertram Opalka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertram Opalka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertram Opalka more than expected).

Fields of papers citing papers by Bertram Opalka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertram Opalka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertram Opalka. The network helps show where Bertram Opalka may publish in the future.

Co-authors

The 25 scholars most cited alongside Bertram Opalka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bertram Opalka Line = papers co-authored together Bertram Opalka links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner Haematologica ·Yahya Al-Matary, Lacramioara Botezatu, Bertram Opalka, Judith Hönes, Robert F. Lams, Aniththa Thivakaran, Judith Schütte, Roelof Koster, Klaus Lennartz, Thomas Schroeder, Rainer Haas, Ulrich Dührsen, Cyrus Khandanpour	2016	111
2	Pluripotent stem cells escape from senescence-associated DNA methylation changes Genome Research ·Carmen Koch, Kristina Reck, Kaifeng Shao, Qiong Lin, Sylvia Joussen, Patrick Ziegler, Gudrun Walenda, Wolf Drescher, Bertram Opalka, Tobias May, Tim H. Brümmendorf, Martin Zenke, Tomo Šarić, Wolfgang Wagner	2012	101
3	Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections Leukemia & lymphoma ·Philipp Schütt, Dieter Brandhorst, Werner Stellberg, Miriam Poser, Peter R. Ebeling, Siemke Müller, Ulrike Buttkereit, Bertram Opalka, Monika Lindemann, Hans Grosse‐Wilde, S. Seeber, Thomas Moritz, Mohammad R. Nowrousian	2006	99
4	Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue Journal of the Neurological Sciences ·Wolfgang Liedtke, Bertram Opalka, C. Zimmermann, Eberhard Lignitz	1993	99
5	Prolonged administration of interferon-alpha in patients with chronic- phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome Blood ·DW Beelen, Ullrich Graeven, AH Elmaagacli, N Niederle, O. Kloke, Bertram Opalka, UW Schaefer	1995	88
6	The Risk of Residual Molecular and Cytogenetic Disease in Patients With Philadelphia-Chromosome Positive First Chronic Phase Chronic Myelogenous Leukemia Is Reduced After Transplantation of Allogeneic Peripheral Blood Stem Cells Compared With Bone Marrow Blood ·Ahmet Elmaağaclı, Dietrich W. Beelen, Bertram Opalka, S. Seeber, U. W. Schaefer	1999	78
7	Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients Clinical Immunology ·Vera Rebmann, Philipp Schütt, Dieter Brandhorst, Bertram Opalka, Tassilo Moritz, Mohammad Reza Nowrousian, Hans Grosse‐Wilde	2007	73
8	Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple Myeloma Clinical Cancer Research ·Mohammad R. Nowrousian, Dieter Brandhorst, C. Sammet, Michaela Kellert, Rainer Daniels, P. Schuett, Miriam Poser, Siemke Mueller, Peter R. Ebeling, Anja Welt, A.R. Bradwell, Ulrike Buttkereit, Bertram Opalka, Michael Flaßhove, Thomas Möritz, S. Seeber	2005	70
9	Prognostic relevance of soluble human leukocyte antigen–G and total human leukocyte antigen class I molecules in lung cancer patients Human Immunology ·Philipp Schütt, Birgit Schütt, Magdalena Switala, Sebastian Bauer, Georgios Stamatis, Bertram Opalka, Wilfried Eberhardt, Martin Schüler, Peter A. Horn, Vera Rebmann	2010	60
10	Loss of expression of theDRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma Genes Chromosomes and Cancer ·Liang Wang, John L. Darling, Jin‐San Zhang, Wanguo Liu, Junqi Qian, David G. Bostwick, Lynn C. Hartmann, Robert B. Jenkins, Walter Bardenhauer, J. Schütte, Bertram Opalka, Jeremy C. Smith	2000	59
11	The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage Annals of Hematology ·AH Elmaagacli, Dietrich W. Beelen, Bertram Opalka, S. Seeber, UW Schaefer	2000	58
12	Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma Blood ·Bertram Opalka, U. Wandl, R. Becher, O. Kloke, M. Nagel‐Hiemke, Thomas Moritz, U. Beer, S. Seeber, N. Niederle	1991	54
13	Impact of interferon alpha‐induced cytogenetic improvement on survival in chronic myelogenous leukaemia British Journal of Haematology ·O. Kloke, N. Niederle, Joseph Qiu, U. Wandl, Thomas Moritz, M. Nagel‐Hiemke, I. Hawig, Bertram Opalka, S. Seeber, R. Becher	1993	51
14	Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma European Journal Of Haematology ·Philipp Schütt, Peter R. Ebeling, Ulrike Buttkereit, Dieter Brandhorst, Bertram Opalka, Mathias Hoiczyk, Michael Flaßhove, J. Hense, Peter Bojko, K. Metz, Tassilo Moritz, S. Seeber, Mohammad R. Nowrousian	2004	41
15	A cloned T-cell line from a tolerant mouse represents a novel antigen-specific suppressor cell type Nature ·Joachim Heuer, Karin Brüner, Bertram Opalka, Eckehart Kölsch	1982	41
16	Precise Localization of Aphidicolin-Induced Breakpoints on the Short Arm of Human Chromosome 3 Genomics ·William Paradee, Chadwick Mullins, Zhanquan He, Thomas W. Glover, Charles Wilke, Bertram Opalka, J. Schütte, Jeremy C. Smith	1995	39
17	Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. PubMed ·Nicole Susann Werner, Zurab Siprashvili, Louise Y.Y. Fong, G. Marquitan, Jan Schröder, Walter Bardenheuer, S. Seeber, Kay Huebner, J. Schütte, Bertram Opalka	2000	38
18	WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. PubMed ·Ahmet Elmaağaclı, Michael Koldehoff, Rudolf Peceny, Ludger Klein‐Hitpaß, H. Ottinger, Dietrich W. Beelen, Bertram Opalka	2005	38
19	Differential Expression of Drug Resistance-Related Genes between Sensitive and Resistant Blasts in Acute Myeloid Leukemia Acta Haematologica ·Lewin Eisele, Ludger Klein‐Hitpaß, N. Chatzimanolis, Bertram Opalka, Tanja Boes, S. Seeber, Tassilo Moritz, Michael Flaßhove	2006	36
20	Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR‐ABL fusion transcripts detected using a new real‐time polymerase chain reaction method British Journal of Haematology ·Ahmet Elmaağaclı, Annette Freist, Meinhard Hahn, Bertram Opalka, S. Seeber, U. W. Schaefer, Dietrich W. Beelen	2001	34

About Bertram Opalka

Bertram Opalka is a scholar working on Hematology, Molecular Biology, Genetics, Genetics and Oncology, having authored 99 papers that have together received 2.3k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (32 papers), Chronic Lymphocytic Leukemia Research (17 papers), Acute Myeloid Leukemia Research (16 papers), Virus-based gene therapy research (15 papers), Eosinophilic Disorders and Syndromes (15 papers), RNA Interference and Gene Delivery (9 papers), Multiple Myeloma Research and Treatments (9 papers) and Genomic variations and chromosomal abnormalities (9 papers). The work is most often cited by research in Hematology (979 citations), Genetics (471 citations), Immunology (505 citations), Oncology (473 citations) and Rheumatology (219 citations). Bertram Opalka has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include S. Seeber, O. Kloke, Dietrich W. Beelen, N. Niederle, Ahmet Elmaağaclı, Tassilo Moritz, Philipp Schütt, J. Schütte, Dieter Brandhorst and UW Schaefer. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia Research, Genomics and European Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact